Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast
Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast
复制标题
乳腺癌原发性鳞状细胞癌的临床病理特征及预后
DOI：
10.1007/s10549-014-3224-z
复制
发表时间：
2015-01-01
影响因子：
3.8
通讯作者：
Cao, Xu-chen
中科院分区：
文献类型：
--
作者：
Liu, Jing;Yu, Yang;Cao, Xu-chen
原发性乳腺鳞状细胞癌（PSCCB）是一种罕见的乳腺癌类型，其临床行为尚未准确表征。本研究的目的是评估本机构患者的患病率、特征、预后和有效治疗方式。检索了天津医科大学肿瘤研究所和医院1985年至2013年的记录，发现29名PSCCB患者（占所有乳腺癌患者的0.086%）。分析了他们的临床病理特征、使用的治疗方法和结果。肿瘤大小中位数为 4.50 厘米。 41.4% 的患者存在腋窝淋巴结转移。中位总生存期为 39 个月（范围 7-144 个月），其中 34.5% 的患者在 5 年后仍存活。中位无复发生存期为 32 个月（范围 4-144 个月），其中 27.6% 的 5 年无复发生存率。根据单变量分析，首次症状出现与首次就诊之间的时间间隔 (TI) (P=0.017)、辅助化疗的使用 (P=0.044) 和 T 分期（P=0.048，T1 与 T2、T3、T4）是总生存期的重要预后因素。 PSCCB 是一种极具侵袭性的疾病，肿瘤体积大、进展快、复发频繁、死亡率高。影像学检查结果不具特异性，很容易被误认为是良性的。基于顺铂的化疗可能有效。这种罕见实体的早期诊断和治疗对于患者预后至关重要。
Primary squamous cell carcinoma of the breast (PSCCB) is a rare type of breast carcinoma, the clinical behavior of which has not been accurately characterized. The aim of this study was to evaluate its prevalence, characteristics, prognosis, and effective treatment modalities in patients attending our institution. The records of the Cancer Institute and Hospital of Tianjin Medical University from 1985 to 2013 were searched and 29 patients with PSCCB (0.086 % of all patients with breast cancer) identified. Their clinicopathological features, treatment methods used, and outcomes were analyzed. The median tumor size was 4.50 cm. Axillary lymph nodes metastases were present in 41.4 % of patients. The median overall survival was 39 months (range 7–144 months), with 34.5 % surviving at 5 years. The median relapse-free survival was 32 months (range 4–144 months), with 27.6 % relapse-free surviving at 5 years. According to univariate analysis, the time interval between onset of the first symptom and first presentation to a health professional (TI) (P= 0.017), use of adjuvant chemotherapy (P= 0.044), and T stage (P= 0.048, T1 vs. T2, T3, T4) were significant prognostic factors for overall survival. PSCCB is an extremely aggressive disease associated with large tumor size, rapid progression, frequent relapse, and a high death rate. Imaging findings are nonspecific and easily misinterpreted as benign. Cisplatin-based chemotherapy may be effective. Early diagnosis and treatment of this rare entity are critical to patient prognosis.